STUDY QUESTION: Do the determinants of insulin sensitivity/resistance differ in women with and without polycystic ovary syndrome (PCOS)?
Introduction
Polycystic ovary syndrome (PCOS), in addition to being a common reproductive-endocrine disorder, is characterized by obesity (Gambineri et al., 2002; Azziz et al., 2004) and insulin resistance (Diamanti-Kandarakis and Dunaif, 2012) . As such, women with PCOS are at elevated risk for type 2 diabetes (Salley et al., 2007) and cardiovascular disease (El Hayek et al., 2016) . Further, insulin resistance may be one of the root causes of both the obesity and the dysregulation of the Hypothalamic-Pituitary-Gonadal axis in PCOS. The etiology of insulin resistance in PCOS is complex, and it may emanate from several genetic (Diamanti-Kandarakis and Dunaif, 2012) and non-genetic sources. Identification of these sources may lead to means for minimizing insulin resistance and associated disease risk.
Abdominal obesity has been suggested as contributing to insulin resistance in PCOS (Carmina et al., 2007) , possibly through inflammation. Subclinical inflammation has been reported in PCOS (Tarkun et al., 2006; Vgontzas et al., 2006) , but remains controversial (Duleba and Dokras, 2012) . Further, whether intra-abdominal adipose tissue (IAAT), the metabolically active compartment, is elevated in PCOS is not clear. Few studies have actually measured IAAT using high-quality imaging techniques. Two of these studies found no difference in IAAT between women with and without PCOS (Barber et al., 2008; Manneras-Holm et al., 2011) . The third, among lean women, found that those with PCOS had significantly less IAAT (Dolfing et al., 2011) . Associations of IAAT and inflammation with insulin resistance in PCOS have not been carefully examined.
Dysfunctional subcutaneous adipose tissue (SAT), as reflected in larger adipocytes and lower circulating adiponectin, has been noted in PCOS (Carmina et al., 2008; Manneras-Holm et al., 2011) , and may contribute to insulin resistance. Both lower adiponectin and diversion of lipid to 'ectopic' depots such as liver and skeletal muscle (Goodpaster et al., 2000 , Shulman, 2014 ) may contribute to insulin resistance in PCOS, but have not been extensively investigated.
Finally, the elevated androgens in PCOS may contribute to insulin resistance. Studies in humans (Elbers et al., 1999; Brochu et al., 2008; Comerford et al., 2012; Mario et al., 2012) and animal models (Holmang et al., 1990) have shown that androgens can directly impair insulin action, as well as adversely affect body composition and fat distribution in ways that may promote insulin resistance (Fontana et al., 2007) .
The purpose of this study was to examine associations of fat distribution, inflammation and testosterone with insulin sensitivity/resistance in women with and without PCOS. We tested the specific hypothesis that among premenopausal women without PCOS, the favorable accumulation of peripheral SAT, as reflected in circulating adiponectin, would have beneficial effects on insulin sensitivity/resistance. In contrast, we hypothesize that women with PCOS have dysfunctional peripheral SAT, and as a result, ectopic adipose in skeletal muscle and circulating testosterone become the main determinants of insulin sensitivity/resistance.
Materials and Methods

Study participants
This cross-sectional/correlational study used baseline data from two previous studies (Goree et al., 2011; Gower et al., 2013) conducted in PCOS (Gower et al., 2013) and overweight, but otherwise healthy women (Goree et al., 2011) . Data from 38 non-PCOS and 30 PCOS premenopausal women were used. The criteria for the diagnosis of PCOS were consistent with the NIH 1990 criteria and included: (i) hyperandrogenism and/or hyperandrogenemia, (ii) oligo-ovulation and (iii) the exclusion of any existing disorders such as Cushing's syndrome, hyperprolactinemia or congenital (non-classic) adrenal hyperplasia. Inclusion requirements were PCOS diagnosis (PCOS group only), BMI >25 kg/m 2 (non-PCOS group only) and ≤45 kg/m 2 (both groups), body weight <136 kg, age 21-49 years, non-diabetic and no weight change >2.3 kg over the past 6 months. Exclusion criteria included PCOS diagnosis (non-PCOS group only), regular exercise >2 hours per week, pregnancy, current breastfeeding, any disorders of glucose or lipid metabolism, use of medication that could affect body composition or glucose metabolism (i.e. oral contraceptives, cholesterol and blood pressure medications), current tobacco use, illegal drug use in last 6 months, history of hypoglycemia, major food allergies or dislikes and a medical history that contra-indicated inclusion. In addition, none of the women with PCOS were receiving medical treatment for the condition or had received medications to mediate the disorder for the previous 3 months. Participants were evaluated for glucose tolerance using a 2-h oral glucose tolerance test. Two women without PCOS had 2-h glucose >140 mg/dl; nine women with PCOS had 2-h glucose >140 mg/dl. (Goodpaster, 2002) . All scans were evaluated by the same image analyst (A.M.G.).
Ethical approval
Insulin sensitivity
The whole-body insulin sensitivity index (WBISI) was derived by obtaining frequent blood samples after consumption of a standardized liquid meal (liquid meal tolerance test; LMTT). Although the euglycemic clamp is considered as the gold standard for assessing insulin sensitivity, an oral test is more physiologically relevant as it engages gastrointestinal hormones, and captures insulin action on both skeletal muscle and liver. The mixed meal has advantages over oral glucose in that it includes fats and proteins that may affect glucose metabolism (Maki et al., 2009) . Insulin sensitivity assessed using liquid mixed meal has been validated against the minimal model (Maki et al., 2011) . Participants fasted 12 h prior to the test. Women without PCOS were tested in the follicular stage of the menstrual cycle. To perform the test, a flexible intravenous catheter was placed in the antecubital space of one arm. At time 'zero', a liquid mixedmacronutrient meal was provided [Carnation Instant Breakfast (Nestle, Minneapolis, MN, USA) and whole milk]. The liquid meal was calculated to provide 7 kcal/kg body weight as 24% fat, 58.6% carbohydrate and 17.4% protein. Subjects were required to consume the meal within 5 min. Blood was drawn at −15 and −5 min before meal ingestion, which began at time zero. Subsequent samples were drawn every 5 min from time zero to 30 min, every 10 min from 30 to 180 min, and at 210 and 240 min. Sera were stored at −85°C. The WBISI was calculated using a formula based on the insulin and glucose values over the course of the meal test (Matsuda and DeFronzo, 1999) . In addition, Homeostasis Model Assessment-Insulin resistance (HOMA-IR) was calculated using a formula based on fasting glucose and fasting insulin: Fasting Glucose (mg/dl) × Fasting Insulin (µU/ml)/405 (Matthews et al., 1985) . HOMA-IR was included as a measure of insulin resistance because it is simple to obtain, and allows for comparison with data from studies where the more demanding meal tolerance test is not feasible.
Analysis of glucose and hormones
Glucose was measured in 3 µl sera by using the glucose oxidase method on a Stanbio SIRRUS analyzer (Stanbio Laboratory, Boerne, TX, USA). This analysis had an inter-assay coefficient of variation (CV) of 3.1% and an intra-assay CV of 1.2%. Insulin was assayed in 50-µl aliquots by using immunofluorescence on a TOSOH AIA-II analyzer (TOSOH Corp, South San Francisco, CA, USA). This analysis had an inter-assay CV of 4.4% and an intra-assay CV of 1.5%. Estradiol and total testosterone were determined by immunofluorescence using the TOSOH with the following CV and sensitivities: estradiol: inter-assay CV 5.4%, intra-assay CV 6.0%, minimum sensitivity 25 pg/ml; testosterone: intra-assay CV 2.4%, inter-assay CV 2.7%, minimum sensitivity 10 ng/dl. Sex hormone binding globulin (SHBG) was determined using an immunoradiometric assay (Siemens Corp., Los Angeles, CA, USA); inter-assay CV 8.0%, intra-assay CV 4.0% and minimum sensitivity 0.68 ng/dl. Free testosterone (pmol/l) was calculated from serum concentrations of total testosterone and SHBG using the method of Sodergard, Backstrom and Shanbhag (Sodergard et al., 1982) . This method is based on the concentration of albumin, the binding capacity of SHBG and the association constants of testosterone for SHBG and albumin, as determined in a sample of normal men and women. Adiponectin was determined in duplicate by a radioimmunoassay (Millipore, St. Charles, MO, USA), which utilizes a polyclonal antibody directed against the oligomeric forms of the hormone (i.e. it will not detect monomeric or globular adiponectin). Adiponectin CV and sensitivity: inter-assay CV 10.9%, intra-assay CV 4.8%, minimum sensitivity 1.29 μg/ml. Serum leptin was measured in duplicate 100-ml aliquots using RIA reagents from Millipore. Leptin CV and sensitivity: mean inter-assay CV 7.9%, mean intraassay CV 9.1%, minimum sensitivity 0.29 ng/ml.
Analysis of markers of inflammation
Circulating inflammation markers were assessed by immunoassay. High sensitivity C-reactive protein (hsCRP) was assessed by turbidometric methodology using a SIRRUS analyzer (Boerne, TX, USA) with reagents obtained from Pointe Scientific (Canton, MI, USA); tumor necrosis factoralpha (TNF-α) using electrochemiluminscence (Meso Scale Discovery, Rockville, MD, USA); and interleukin (IL-6) using electrochemiluminscence (Meso Scale Discovery). Mean inter-assay CVs are 2.1%, 5.5% and 9.7%, respectively. Mean intra-assay CVs are 7.49%, 7.61% and 6.68%, respectively. Minimum detectable concentrations for each assay are 0.05 mg/l, 0.51 pg/ml and 0.25 pg/ml, respectively.
Statistical analyses
This was a hypothesis generating study, with the intent of using the results to generate sample size for future studies with the effect size we provide. As such, power or sample size analyses were not included. Analyses were performed with SAS version 9 (Cary, NC, USA). Data were logtransformed as necessary to correct for skewness (HOMA-IR, WBISI, thigh muscle, IAAT, IMAT, CRP, IL-6, adiponectin, estradiol, testosterone, free testosterone). ANOVA was used to compare baseline characteristics between women with and without PCOS. ANCOVA was used to compare groups after adjusting for total fat mass and in the case of IMAT and PMAT, also for muscle cross-sectional area. Pearson partial correlation analyses, controlling for total body fat mass, were employed to examine the relationships of WBISI and HOMA-IR with measures of body composition, body fat distribution, markers of inflammation and serum hormone concentrations within each group of women. Because analyses indicated a unique association of PMAT with WBISI and HOMA-IR in women with PCOS, we also examined whether PMAT was associated with thigh SAT (Pearson partial correlation adjusted for fat mass and thigh muscle) within each group of women.
After identifying the variables that were significantly associated with WBISI and HOMA-IR, stepwise multiple linear regression analysis was used to identify the independent variables that best predicted WBISI and HOMA-IR within each group. The variables that were entered were total body fat, thigh muscle cross-sectional area, thigh subcutaneous adipose tissue, IAAT, PMAT, free testosterone and adiponectin.
Results
Participant characteristics
All women without PCOS were overweight or obese. Within the PCOS group, five participants were normal weight (BMI ≤24.9) and the remaining (n = 25) participants were overweight/obese. All participants were premenopausal (aged 21-49 years) and were African American (54.6%) or European American (45.1%). Participant characteristics are shown in Table I by group. Not all outcomes were available for all participants; in the PCOS group, sample size ranged from 24 to 30, and in the women without PCOS, sample size ranged from 35 to 38. Significant between-group differences were noted for TNF-α, total testosterone and free testosterone.
Correlations of insulin sensitivity/resistance with measures of body composition/fat distribution, hormones and markers of inflammation
Results from partial correlation analysis for WBISI and HOMA-IR are shown in Tables II and III by group. Among women with PCOS, WBISI was inversely associated with PMAT, and positively associated with thigh SAT; the inverse association with free testosterone approached significance (P = 0.056). HOMA-IR was positively associated with PMAT and free testosterone, and inversely with thigh SAT. Among women without PCOS, WBISI was positively associated with adiponectin and thigh SAT, and inversely associated with free testosterone. HOMA-IR was inversely associated with thigh SAT and adiponectin, and positively associated with free testosterone. In women with PCOS, thigh SAT was inversely associated with PMAT (−0.587, P < 0.01; adjusted for total body fat and thigh muscle); this association was not observed in women without PCOS (0.003, P = 0.986).
Variables that best predicted insulin sensitivity/resistance
Stepwise multiple linear regression analysis among women with PCOS indicated that both WBISI and HOMA-IR were best predicted by PMAT (partial R 2 of 0.40 and 0.49, respectively; P < 0.001; data not shown), with a small amount of residual variance (8%) in HOMA-IR explained by IAAT (P < 0.05). Free testosterone entered the model for HOMA-IR (partial R 2 of 0.08) but was not significant (P = 0.051). Further controlled for thigh muscle cross-sectional area. **P < 0.01, ***P < 0.001.
predicted by adiponectin, total body fat and thigh SAT (P ≤ 0.001 for all). In addition, free testosterone explained 5% of the variance in WBISI (P < 0.01).
Discussion
Insulin resistance is the root cause of obesity and comorbidities in PCOS. Determining the cause of insulin resistance could lead to potential therapies. The main finding of this study was that PMAT, an ectopic adipose depot adjacent to skeletal muscle, may play a unique role in determining insulin sensitivity/resistance in women with PCOS. In contrast, the protective effect of thigh SAT on insulin sensitivity/ resistance, dominant in women without PCOS, is less apparent in those with PCOS. In this study, thigh PMAT was the strongest determinant of insulin sensitivity/resistance in the PCOS group (Fig. 1) . Few studies have examined the association of all three thigh fat compartments (subcutaneous, intermuscular and peri-muscular) with insulin sensitivity/resistance. While there is general consensus regarding the relatively positive influence of thigh SAT, findings related to the relationship of thigh IMAT and PMAT are less clear (Goodpaster et al., 2000; Goss and Gower, 2012) . In a heterogeneous sample of men and women, both thigh IMAT and PMAT were inversely related to insulin sensitivity; however, these associations were not significant after adjusting for total body fat (Goodpaster et al., 2000) . Our group previously reported that thigh IMAT, but not PMAT, was inversely associated with insulin sensitivity in a sample of healthy postmenopausal women, a relationship that remained significant after adjusting for total body fat (Goss and Gower, 2012) . Discrepancies between study findings may be the result of variation in sample population or measurement techniques. The mechanisms through which thigh PMAT may interfere with insulin action are not clear; however, it has been hypothesized that reduced blood flow in and around the thigh muscle, increased local concentrations of free fatty acids or pro-inflammatory cytokines, as well as a alterations in insulin diffusion capability, may impair insulin action (Ragheb et al., 2009 ). To our knowledge, this is the first study to examine thigh adipose tissue subcompartments in relation to insulin sensitivity/resistance in premenopausal women with PCOS.
Our results also suggest that dysfunctional subcutaneous adipose tissue in PCOS may contribute to insulin resistance. In general, among CRP, C-reactive protein; IL-6, Interleukin-6; TNF-α, tumor necrosis factor-alpha. a P = 0.056. *P < 0.05, **P < 0.01, ***P < 0.001.
premenopausal women, a preponderance of subcutaneous adipose in the hip and thigh region is thought to contribute to their relatively high insulin sensitivity and favorable metabolic health (Snijder et al., 2005; Goss and Gower, 2012; Pinnick et al., 2014) . In this study, the total amount of thigh SAT did not differ between groups, but only in women without PCOS was thigh SAT independently associated with insulin sensitivity/resistance. Further, only in women with PCOS was PMAT associated with thigh SAT. Taken together, these observations suggest that women with PCOS allocated lipid to PMAT at the expense of thigh SAT, which had an adverse effect on insulin sensitivity/resistance. The influence of thigh SAT on insulin sensitivity/resistance was also reflected in associations with adiponectin. Adiponectin was the strongest hormonal correlate of both WBISI and HOMA-IR in women without PCOS (Fig. 2) . Adiponectin is a marker for functional adipose tissue (Kadowaki et al., 2008; Martella et al., 2014) , and when secreted, may play a role in inflammation, glucose metabolism and insulin sensitivity (Diez and Iglesias, 2003) . In this study, adiponectin concentrations did not differ between women with and without PCOS, but the relationship of adiponectin to insulin sensitivity/resistance was completely absent in women with PCOS. Research is needed to explore the role of adiponectin in adipose tissue function and processes regulating insulin action in women with PCOS.
Free testosterone appeared to explain a small amount of variance in insulin sensitivity/resistance in both groups of women. The most likely explanation for this is an insulin-mediated depression in sex hormone binding globulin. Blockage of androgen synthesis in PCOS has no effect (Dunaif et al., 1990; Diamanti-Kandarakis et al., 1995; Lemieux et al., 1999) or only a minor effect (Elkind-Hirsch et al., 1993; Moghetti et al., 1996; Cagnacci et al., 1999) on insulin sensitivity, and testosterone alone cannot explain insulin resistance in PCOS (Diamanti-Kandarakis and Dunaif, 2012) . Taken together, data do not point to a strong role for testosterone in insulin sensitivity/resistance in women.
Our study is only the fourth study using imaging techniques to compare IAAT in women with and without PCOS. We, like two of the other studies (Barber et al., 2008; Manneras-Holm et al., 2011) , found no difference between groups. The fourth study, of exclusively lean women, found significantly lower IAAT in women with PCOS (Dolfing et al., 2011) . Our data support a minor role at best for IAAT in determining HOMA-IR in women with PCOS. Thus, existing data suggest that the obesity of PCOS may mask a fat distribution characterized by less IAAT, and that IAAT cannot explain the insulin resistance of PCOS.
Our data supported neither higher inflammation in PCOS nor an independent contribution of inflammation to insulin resistance. Although higher systemic inflammation has been reported in PCOS (Gonzalez et al., 2009 ), this concept is controversial (Duleba and Dokras, 2012) , with data possibly being confounded by obesity and/ or participant heterogeneity regarding PCOS diagnostic criteria.
Strengths of the study were the strong measures of body composition and body fat distribution. Limitations were the small sample size, difference in range of BMI between the two groups and the use of surrogate measures of insulin sensitivity/resistance rather than the gold standard euglycemic clamp.
To conclude, results indicate that correlates of insulin sensitivity/ resistance differ in women with and without PCOS. These differences may provide insight into cause-and-effect in both groups. It is known that a genetic factor in skeletal muscle confers insulin resistance in PCOS, with resultant elevated post-prandial insulin secretion. This combination of inherent insulin resistance and compensatory elevated insulin response, perhaps in concert with elevated testosterone, may have diverse effects on body composition, fat distribution and endocrine factors, leading to preferential deposition of fat within the muscle fascia (PMAT). With this same logic, women without PCOS may preferentially deposit and expand subcutaneous thigh fat in response to adequate levels of both insulin sensitivity and estrogen. However, it is possible that fatty infiltration of skeletal muscle impairs both metabolic and physical function. Our data have shown that an insulin-lowering diet selectively depletes IMAT and improves insulin sensitivity in women with PCOS, even without weight loss (Gower et al., 2013; Goss et al., 2014) . Further research with such insulin-lowering diets is needed both to probe mechanisms and to develop diet guidelines for improving the metabolic heath and quality of life of women with PCOS. Figure 2 Whole-body insulin sensitivity index (WBISI) is related to adiponectin in women without polycystic ovary syndrome (simple correlation, r = 0.54, P < 0.001).
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